{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-073312","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2024-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.382986+00:00","generated_at":"2026-06-01T04:27:34.238995+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Kyverna presents data update on KYV-101 CAR T therapy at EULAR symposium","bullets":["CEO Peter Maag introduced symposium; external speakers presented long-term clinical experience with anti-CD19 CAR T in autoimmune diseases.","KYV-101 data covered experience across multiple autoimmune diseases and sites, presented by James Chung, MD, PhD of Kyverna.","Panel discussion featured academic and Kyverna experts on KYV-101's potential in rheumatologic autoimmune indications.","No specific numerical efficacy or safety results were disclosed in the furnished presentation materials."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-073312","json":"https://secwatch.observer/filing/0000950170-24-073312.json","markdown":"https://secwatch.observer/filing/0000950170-24-073312.md","text":"https://secwatch.observer/filing/0000950170-24-073312.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000095017024073312/0000950170-24-073312-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000095017024073312/kytx-20240614.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:27:34.238995+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}